B+L to become primary supplier for surgical ophthalmology
LAVAL, QC, Nov.10, 2014 /CNW Telbec/ - Bausch + Lomb Canada, a division of Valeant Canada, today announced that it has been awarded a five-year, primary supplier contract by Mohawk Shared Services to supply surgical ophthalmology devices and supplies to eight Ontario cataract programs.
Mohawk Shared Services in collaboration with the Northwest Supply Chain awarded Bausch + Lomb Canada a prime supplier award that will provide state of the art surgical ophthalmology technologies and cost efficiencies to Mohawk member hospitals including: St. Michael's Hospital – Toronto, St. Joseph's HealthCare – Hamilton, Joseph Brant Hospital – Burlington, Niagara Health System, St. Mary's General Hospital – Kitchener, Brant Community Healthcare – Brantford and Northwest Supply Chain Hospitals including Thunder Bay Regional Hospital – Thunder Bay, and Wilson Memorial, Marathon.
The primary supplier contract provides for the supply of Bausch + Lomb's and recently acquired CROMA Pharma's family of Monofocal intra-ocular lenses (IOL's), Viscoelastics, Surgical Instruments, Blades, and Toric IOL's. Unique to the Bausch + Lomb portfolio is the enVista family of hydrophobic acrylic (IOLs), the first and only Health Canada and FDA-approved IOL with a "No-Glistening" claim, a specific property of Bausch + Lomb. In addition, under the agreement, member hospitals will also be able to introduce the Stellaris phacoemulsification platform, for cataract surgery, over its five-year term providing further cost efficiency to Mohawk and Northwest Supply Chain member hospitals.
"This agreement allows us to supply the Mohawk Shared Services and Northwest Supply Chain member hospitals and their cataract programs with our broad array of surgical ophthalmology products and ensures the provision of leading edge surgical eye health technologies to thousands of Ontario patients", said Charles Perez, Vice-President and General Manager of Bausch + Lomb Canada.
About Bausch + Lomb Canada
Bausch + Lomb Canada, a division of Valeant Canada, is solely dedicated to protecting, enhancing and restoring people's eyesight. Our mission is simple yet powerful: Helping you see better to live better. The company is a leading global eye health organization and one of the best-known and most respected healthcare brands. Our core businesses include ophthalmic pharmaceuticals, contact lenses and lens care products, and ophthalmic surgical devices and instruments. Bausch + Lomb globally develops, manufactures and markets one of the most comprehensive product portfolios in our industry, which are available everywhere in Canada and in more than 100 countries.
About Valeant Canada
Valeant Canada is a subsidiary of Valeant Pharmaceuticals International, Inc., a multinational specialty pharmaceutical company that develops manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology, and branded generics. More information about Valeant Canada can be found at www.valeantcanada.com.
This news release is available at www.cnw.ca.
SOURCE: Bausch + Lomb Canada
For further information: Marie-Christine Garon, Valeant Canada, Mariechristine.email@example.com, 514-409-0031